Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Tamoxifen × Endocrine × Clear all

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 39 Tumor-Agnostic 2 Thoracic 1 Sarcoma 1 Gynecologic 1 Genitourinary 1 Endocrine 1

Conditions

Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 20 lutetium Lu 177 dotatate 10 pasireotide 9 Octreotide 8 surufatinib 7 lanreotide 7 pembrolizumab 5 amino-acid, glucose, and electrolyte solution 5 Sunitinib 5 Paclitaxel 5 Nivolumab 5 Injections 5 Carboplatin 5 3-Iodobenzylguanidine 5 relacorilant 4 fosbretabulin 4 Thyrotropin Alfa 4 Temozolomide 4 Fulvestrant 4 Data Collection 4 Cisplatin 4 selpercatinib 3 dabrafenib 3 Mifepristone 3 Etoposide 3 Corlux 3 Cabergoline 3 177Lu-octreotide, DOTA(0)-Tyr(3)- 3 vandetanib 2 trametinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02753686 2023-02-15

Treat ER+ight

Novartis

Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡